Sanofi (NASDAQ:SNY) Hits New 1-Year Low – Here’s Why

Sanofi (NASDAQ:SNY) shares hit a new 52-week low during mid-day trading on Friday . The company traded as low as $44.01 and last traded at $44.01, with a volume of 93153 shares. The stock had previously closed at $45.00.

Analysts Set New Price Targets

SNY has been the topic of several research reports. Bank of America lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Thursday, February 12th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday, December 8th. UBS Group reiterated a “neutral” rating on shares of Sanofi in a report on Friday, January 16th. Barclays downgraded Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. Finally, Guggenheim downgraded Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. Five research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $62.67.

Sanofi Stock Down 1.0%

The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The firm has a market cap of $108.66 billion, a PE ratio of 12.38, a P/E/G ratio of 1.15 and a beta of 0.45. The firm’s 50 day moving average is $47.31 and its 200-day moving average is $48.46.

Hedge Funds Weigh In On Sanofi

Several institutional investors have recently added to or reduced their stakes in the business. Brighton Jones LLC grew its holdings in Sanofi by 52.6% in the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after buying an additional 1,869 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Sanofi by 107.2% during the 1st quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after acquiring an additional 15,791 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Sanofi by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock worth $2,732,000 after acquiring an additional 752 shares during the last quarter. Sivia Capital Partners LLC grew its holdings in Sanofi by 5.4% in the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after purchasing an additional 347 shares during the period. Finally, Moors & Cabot Inc. increased its position in Sanofi by 3.9% during the second quarter. Moors & Cabot Inc. now owns 8,307 shares of the company’s stock worth $401,000 after purchasing an additional 313 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.